Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Hodgkin Disease 50Lymphoma 45Lymphoma, Large B-Cell, Diffuse 10Lymphoma, Non-Hodgkin 9Lymphoma, Large-Cell, Immunoblastic 6Lymphoma, Follicular 6HIV Infections 5Acquired Immunodeficiency Syndrome 4Recurrence 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Dendritic Cell Sarcoma, Interdigitating 2Cardiotoxicity 2Burkitt Lymphoma 2Waldenstrom Macroglobulinemia 1Nervous System Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Multiple Myeloma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Diseases 1Disease 1AIDS-Related Complex 1

Interventions

tetulomab tetraxetan lu-177 2Lutetium 2Zidovudine 1Vinblastine 1Lutetium-177 1Filgrastim 1Doxorubicin 1Dacarbazine 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
AIDS-Related Complex × Bleomycin × Lymphoid × Clear all
NCT00000626 2021-10-27

Phase II Study of Filgrastim (G-CSF) Plus ABVD in the Treatment of HIV-Associated Hodgkin's Disease

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 2 Completed
27 enrolled
Lymphoid

Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Hodgkin Disease, HIV Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡